Calliditas Therapeutics AB today announced that its management will be attending the following upcoming investor and industry conferences.
| STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics (Formerly known as Pharmalink) AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences: Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024. Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings. World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA. Maria Törnsén, President North America, will be moderating a panel, entitled “Partnering in the rare disease space - industry perspective”. LSX World Congress, Monday, April 29, 2024, in London. Maria Törnsén, President North America, will participate in a panel discussion entitled “Commercial Models of The Future and How the Biopharma Launch Landscape Is Changing: Expert Panel Discussion”. The same day, Renée Aguiar-Lucander, CEO, will participate in a panel discussion entitled “The Inflation Reduction Act and its Potential Impact on EU Biotech & Pharma Companies: Demystifying the Future”. Additionally, Calliditas’ Group General Counsel, Brian Gorman, will participate in a panel discussion entitled “Importance of IP Due-Diligence in Deals Within the US”. One-on-one meetings with management will be available. CONTACT: For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel : +46 76 403 35 43, Email : asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact persons set out above, on April 9, 2023, at 13.00 p.m. CET. This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Calliditas Therapeutics | ||||
Company Codes: Bloomberg:CALTX@SS, ISIN:SE0010441584, NASDAQ-NMS:CALT, RICS:CALTX.ST |
View original content:
